These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 28941394

  • 1. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.
    Braz J Infect Dis; 2017; 21(6):627-637. PubMed ID: 28941394
    [Abstract] [Full Text] [Related]

  • 2. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 3. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.
    J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
    [Abstract] [Full Text] [Related]

  • 4. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA, Bassetti M, Duncan LR, Castanheira M.
    J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct 01; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D, Pfaller MA, Castanheira M, Flamm RK.
    Microb Drug Resist; 2018 Jun 01; 24(5):563-577. PubMed ID: 29039729
    [Abstract] [Full Text] [Related]

  • 7. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 01; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018).
    Pfaller M, Shortridge D, Chen WT, Sader H, Castanheira M.
    Infect Drug Resist; 2022 Jun 01; 15():6739-6753. PubMed ID: 36444213
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
    Farrell DJ, Flamm RK, Sader HS, Jones RN.
    Antimicrob Agents Chemother; 2013 Dec 01; 57(12):6305-10. PubMed ID: 24100499
    [Abstract] [Full Text] [Related]

  • 11. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    J Infect; 2014 Sep 01; 69(3):266-77. PubMed ID: 24780763
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H, Körber-Irrgang B, Kresken M, German Ceftolozane/Tazobactam Study Group.
    Int J Antimicrob Agents; 2018 Feb 01; 51(2):227-234. PubMed ID: 28705666
    [Abstract] [Full Text] [Related]

  • 13. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Antimicrob Agents Chemother; 2019 Apr 01; 63(4):. PubMed ID: 30617091
    [Abstract] [Full Text] [Related]

  • 14. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.
    Antimicrob Agents Chemother; 2018 Mar 01; 62(3):. PubMed ID: 29263073
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program.
    Shortridge D, Pfaller MA, Castanheira M, Flamm RK.
    Diagn Microbiol Infect Dis; 2018 Oct 01; 92(2):158-163. PubMed ID: 29891184
    [Abstract] [Full Text] [Related]

  • 16. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep 01; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec 01; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 18. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
    Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M.
    J Glob Antimicrob Resist; 2022 Dec 01; 31():98-103. PubMed ID: 35988706
    [Abstract] [Full Text] [Related]

  • 19. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group.
    Eur J Clin Microbiol Infect Dis; 2021 Dec 01; 40(12):2533-2541. PubMed ID: 34291323
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 01; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.